Dengue virus envelope protein serotype 4 (DENV4 E protein)

The **Dengue virus envelope protein serotype 4** is a ~53 kDa surface glycoprotein that forms dimers and covers the virion surface of dengue virus serotype 4 (DENV4), a member of the Flaviviridae family[2][4]. It is organized into three domains (DI, DII, DIII) with domain III (ED3) containing critical neutralizing epitopes and receptor recognition sites[1][2]. The E protein mediates virus attachment to host cells, triggers membrane fusion for viral entry (via pH-triggered conformational rearrangement), and is the principal antigenic determinant eliciting neutralizing antibody responses[2][3][4]. Knowledge of the DENV4 E protein structure has advanced vaccine and antibody therapeutic development, although antibody-dependent enhancement presents significant safety and efficacy challenges[2][1]. Targeting conserved and serotype-specific epitopes, especially within domain III, is an active focus for broadly neutralizing vaccine and monoclonal antibody strategies[1][5].

Other names

DENV4 envelope glycoproteinE protein (DENV4)Envelope protein domain III (when referring specifically to the immunodominant domain)DENV4 E

Neutralizing monoclonal antibodies: Block viral entry by binding to epitopes in envelope protein domain III, preventing attachment or conformational changes required for membrane fusion[1][5] Experimental vaccines: Induce protective antibodies targeting E protein surface epitopes